{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:35:29Z","timestamp":1759332929168,"version":"build-2065373602"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,30]]},"DOI":"10.7759\/cureus.93587","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T18:17:07Z","timestamp":1759256227000},"source":"Crossref","is-referenced-by-count":0,"title":["The Role of Eyelid Margin Vascularity in Meibomian Gland Dysfunction Diagnosis and Management"],"prefix":"10.7759","author":[{"given":"Nikolaos","family":"Kappos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilias","family":"Georgalas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Papaconstantinou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Droutsas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6997e","article-title":"The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD","volume":"52","author":"Schaumberg DA","year":"2011","unstructured":"Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011, 52:1994-2005. 10.1167\/iovs.10-6997e","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6997b","article-title":"The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee","volume":"52","author":"Nelson JD","year":"2011","unstructured":"Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, Foulks GN. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011, 52:1930-7. 10.1167\/iovs.10-6997b","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.02.024","article-title":"Meibomian gland dysfunction and dry eye are similar but different based on a population-based study: the Hirado-Takushima study in Japan","volume":"207","author":"Arita R","year":"2019","unstructured":"Arita R, Mizoguchi T, Kawashima M, et al.. Meibomian gland dysfunction and dry eye are similar but different based on a population-based study: the Hirado-Takushima study in Japan. Am J Ophthalmol. 2019, 207:410-8. 10.1016\/j.ajo.2019.02.024","journal-title":"Am J Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-020-01489-z","article-title":"Analysis of tear inflammatory molecules and clinical correlations in evaporative dry eye disease caused by meibomian gland dysfunction","volume":"40","author":"Wu X","year":"2020","unstructured":"Wu X, Chen X, Ma Y, et al.. Analysis of tear inflammatory molecules and clinical correlations in evaporative dry eye disease caused by meibomian gland dysfunction. Int Ophthalmol. 2020, 40:3049-58. 10.1007\/s10792-020-01489-z","journal-title":"Int Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-23345","article-title":"Inflamed obstructive meibomian gland dysfunction causes ocular surface inflammation","volume":"59","author":"Suzuki T","year":"2018","unstructured":"Suzuki T. Inflamed obstructive meibomian gland dysfunction causes ocular surface inflammation. Invest Ophthalmol Vis Sci. 2018, 59:DES94-101. 10.1167\/iovs.17-23345","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/1120672118795399","article-title":"Cytokine expression in tears of patients with glaucoma or dry eye disease: a prospective, observational cohort study","volume":"29","author":"Benitez-Del-Castillo J","year":"2019","unstructured":"Benitez-Del-Castillo J, Cantu-Dibildox J, Sanz-Gonz\u00e1lez SM, Zan\u00f3n-Moreno V, Pinazo-Duran MD. Cytokine expression in tears of patients with glaucoma or dry eye disease: a prospective, observational cohort study. Eur J Ophthalmol. 2019, 29:437-43. 10.1177\/1120672118795399","journal-title":"Eur J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3341\/jkos.2019.60.12.1140","article-title":"The correlation between tear matrix metalloproteinase-9 concentration and clinical findings in dry eye disease","volume":"60","author":"Kim HR","year":"2019","unstructured":"Kim HR, Lee HK. The correlation between tear matrix metalloproteinase-9 concentration and clinical findings in dry eye disease. J Korean Ophthalmol Soc. 2019, 60:1140-7. 10.3341\/jkos.2019.60.12.1140","journal-title":"J Korean Ophthalmol Soc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.07.010","article-title":"The pathophysiology of dry eye disease: what we know and future directions for research","volume":"124","author":"Pflugfelder SC","year":"2017","unstructured":"Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology. 2017, 124:S4-13. 10.1016\/j.ophtha.2017.07.010","journal-title":"Ophthalmology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.13.11","article-title":"Hyperkeratinization and proinflammatory cytokine expression in meibomian glands induced by Staphylococcus aureus","volume":"62","author":"Chen H","year":"2021","unstructured":"Chen H, Gao H, Xie HT, Liu ST, Huang YK, Zhang MC. Hyperkeratinization and proinflammatory cytokine expression in meibomian glands induced by Staphylococcus aureus. Invest Ophthalmol Vis Sci. 2021, 62:11. 10.1167\/iovs.62.13.11","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39929-1","article-title":"Glycosylation of Staphylococcus aureus cell wall teichoic acid is influenced by environmental conditions","volume":"9","author":"Mistretta N","year":"2019","unstructured":"Mistretta N, Brossaud M, Telles F, Sanchez V, Talaga P, Rokbi B. Glycosylation of Staphylococcus aureus cell wall teichoic acid is influenced by environmental conditions. Sci Rep. 2019, 9:3212. 10.1038\/s41598-019-39929-1","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11060356","article-title":"An eye on Staphylococcus aureus toxins: roles in ocular damage and inflammation","volume":"11","author":"Astley R","year":"2019","unstructured":"Astley R, Miller FC, Mursalin MH, Coburn PS, Callegan MC. An eye on Staphylococcus aureus toxins: roles in ocular damage and inflammation. Toxins (Basel). 2019, 11:356. 10.3390\/toxins11060356","journal-title":"Toxins (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/WOX.0b013e3182439613","article-title":"Oxidative stress and antioxidant defense","volume":"5","author":"Birben E","year":"2012","unstructured":"Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012, 5:9-19. 10.1097\/WOX.0b013e3182439613","journal-title":"World Allergy Organ J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020292","article-title":"Oxidative stress in the anterior ocular diseases: diagnostic and treatment","volume":"11","author":"Dammak A","year":"2023","unstructured":"Dammak A, Pastrana C, Martin-Gil A, et al.. Oxidative stress in the anterior ocular diseases: diagnostic and treatment. Biomedicines. 2023, 11:292. 10.3390\/biomedicines11020292","journal-title":"Biomedicines"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4274\/tjo.galenos.2021.66168","article-title":"Dry eye and meibomian gland dysfunction in neovascular age-related macular degeneration patients treated with intravitreal injections","volume":"52","author":"K\u0131yat P","year":"2022","unstructured":"K\u0131yat P, Palamar M, Nal\u00e7ac\u0131 S, Akk\u0131n C. Dry eye and meibomian gland dysfunction in neovascular age-related macular degeneration patients treated with intravitreal injections. Turk J Ophthalmol. 2022, 52:157-61. 10.4274\/tjo.galenos.2021.66168","journal-title":"Turk J Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13900","article-title":"Ocular manifestations of rosacea: a clinical review","volume":"49","author":"Tavassoli S","year":"2021","unstructured":"Tavassoli S, Wong N, Chan E. Ocular manifestations of rosacea: a clinical review. Clin Exp Ophthalmol. 2021, 49:104-17. 10.1111\/ceo.13900","journal-title":"Clin Exp Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/srt.13411","article-title":"A retrospective study on VISIA of telangiectasia network in 378 cases of rosacea of the upper eyelid","volume":"29","author":"Yang F","year":"2023","unstructured":"Yang F, Song D, Wang L, Jiang X. A retrospective study on VISIA of telangiectasia network in 378 cases of rosacea of the upper eyelid. Skin Res Technol. 2023, 29:e13411. 10.1111\/srt.13411","journal-title":"Skin Res Technol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2015.1088953","article-title":"Morphological and functional evaluation of meibomian gland dysfunction in rosacea patients","volume":"41","author":"Machali\u0144ska A","year":"2016","unstructured":"Machali\u0144ska A, Zakrzewska A, Markowska A, Safranow K, Wiszniewska B, Parafiniuk M, Machali\u0144ski B. Morphological and functional evaluation of meibomian gland dysfunction in rosacea patients. Curr Eye Res. 2016, 41:1029-34. 10.3109\/02713683.2015.1088953","journal-title":"Curr Eye Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120937252","article-title":"Update on the pathogenesis and management of ocular rosacea: an interdisciplinary review","volume":"31","author":"Jabbehdari S","year":"2021","unstructured":"Jabbehdari S, Memar OM, Caughlin B, Djalilian AR. Update on the pathogenesis and management of ocular rosacea: an interdisciplinary review. Eur J Ophthalmol. 2021, 31:22-33. 10.1177\/1120672120937252","journal-title":"Eur J Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1199440","article-title":"Impacts of gender and age on meibomian gland in aged people using artificial intelligence","volume":"11","author":"Huang B","year":"2023","unstructured":"Huang B, Fei F, Wen H, et al.. Impacts of gender and age on meibomian gland in aged people using artificial intelligence. Front Cell Dev Biol. 2023, 11:1199440. 10.3389\/fcell.2023.1199440","journal-title":"Front Cell Dev Biol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030527","article-title":"Morphology of meibomian glands in a 65-year-old Norwegian population without dry eye disease","volume":"11","author":"Chen X","year":"2022","unstructured":"Chen X, Badian RA, Hynne H, Tashbayev B, Hove LH, Jensen JL, Utheim TP. Morphology of meibomian glands in a 65-year-old Norwegian population without dry eye disease. J Clin Med. 2022, 11:527. 10.3390\/jcm11030527","journal-title":"J Clin Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411538","article-title":"Vascular ageing: mechanisms, risk factors, and treatment strategies","volume":"24","author":"Ya J","year":"2023","unstructured":"Ya J, Bayraktutan U. Vascular ageing: mechanisms, risk factors, and treatment strategies. Int J Mol Sci. 2023, 24:11538. 10.3390\/ijms241411538","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000000530","article-title":"Dry eye in postmenopausal women: a hormonal disorder","volume":"23","author":"Sriprasert I","year":"2016","unstructured":"Sriprasert I, Warren DW, Mircheff AK, Stanczyk FZ. Dry eye in postmenopausal women: a hormonal disorder. Menopause. 2016, 23:343-51. 10.1097\/GME.0000000000000530","journal-title":"Menopause"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000815","article-title":"Epidemiology of meibomian gland dysfunction in an elderly population","volume":"35","author":"Alghamdi YA","year":"2016","unstructured":"Alghamdi YA, Mercado C, McClellan AL, Batawi H, Karp CL, Galor A. Epidemiology of meibomian gland dysfunction in an elderly population. Cornea. 2016, 35:731-5. 10.1097\/ICO.0000000000000815","journal-title":"Cornea"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S146556","article-title":"Efficacy of intra-meibomian gland injection of the anti-VEGF agent bevacizumab for the treatment of meibomian gland dysfunction with lid-margin vascularity","volume":"12","author":"Jiang X","year":"2018","unstructured":"Jiang X, Wang Y, Lv H, Liu Y, Zhang M, Li X. Efficacy of intra-meibomian gland injection of the anti-VEGF agent bevacizumab for the treatment of meibomian gland dysfunction with lid-margin vascularity. Drug Des Devel Ther. 2018, 12:1269-79. 10.2147\/DDDT.S146556","journal-title":"Drug Des Devel Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S222451","article-title":"Influence of eyelid pigmentation on the diagnosis of meibomian gland dysfunction","volume":"13","author":"Blumberg MJ","year":"2019","unstructured":"Blumberg MJ, Millen AE, Patel SP. Influence of eyelid pigmentation on the diagnosis of meibomian gland dysfunction. Clin Ophthalmol. 2019, 13:1815-21. 10.2147\/OPTH.S222451","journal-title":"Clin Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2016.03.002","article-title":"Exploring the predisposition of the Asian eye to development of dry eye","volume":"14","author":"Craig JP","year":"2016","unstructured":"Craig JP, Wang MT, Kim D, Lee JM. Exploring the predisposition of the Asian eye to development of dry eye. Ocul Surf. 2016, 14:385-92. 10.1016\/j.jtos.2016.03.002","journal-title":"Ocul Surf"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3182a02e0e","article-title":"Assessment of signs of anterior blepharitis using standardized color photographs","volume":"32","author":"Bunya VY","year":"2013","unstructured":"Bunya VY, Brainard DH, Daniel E, et al.. Assessment of signs of anterior blepharitis using standardized color photographs. Cornea. 2013, 32:1475-82. 10.1097\/ICO.0b013e3182a02e0e","journal-title":"Cornea"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.06.025","article-title":"Development of definitive and reliable grading scales for meibomian gland dysfunction","volume":"169","author":"Arita R","year":"2016","unstructured":"Arita R, Minoura I, Morishige N, et al.. Development of definitive and reliable grading scales for meibomian gland dysfunction. Am J Ophthalmol. 2016, 169:125-37. 10.1016\/j.ajo.2016.06.025","journal-title":"Am J Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/60\/10\/R211","article-title":"Functional optical coherence tomography: principles and progress","volume":"60","author":"Kim J","year":"2015","unstructured":"Kim J, Brown W, Maher JR, Levinson H, Wax A. Functional optical coherence tomography: principles and progress. Phys Med Biol. 2015, 60:R211-37. 10.1088\/0031-9155\/60\/10\/R211","journal-title":"Phys Med Biol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.05.017","article-title":"Optical coherence tomography angiography for anterior segment vasculature imaging","volume":"122","author":"Ang M","year":"2015","unstructured":"Ang M, Sim DA, Keane PA, Sng CC, Egan CA, Tufail A, Wilkins MR. Optical coherence tomography angiography for anterior segment vasculature imaging. Ophthalmology. 2015, 122:1740-7. 10.1016\/j.ophtha.2015.05.017","journal-title":"Ophthalmology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.13.6.6","article-title":"Quantitative assessment of lid margin vascularity using swept-source optical coherence tomography angiography","volume":"13","author":"Hu M","year":"2024","unstructured":"Hu M, Wang C, Li Y, et al.. Quantitative assessment of lid margin vascularity using swept-source optical coherence tomography angiography. Transl Vis Sci Technol. 2024, 13:6. 10.1167\/tvst.13.6.6","journal-title":"Transl Vis Sci Technol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14010047","article-title":"The latest updates in swept-source optical coherence tomography angiography","volume":"14","author":"Xia F","year":"2023","unstructured":"Xia F, Hua R. The latest updates in swept-source optical coherence tomography angiography. Diagnostics (Basel). 2023, 14:47. 10.3390\/diagnostics14010047","journal-title":"Diagnostics (Basel)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman RM","year":"2000","unstructured":"Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000, 118:615-21. 10.1001\/archopht.118.5.615","journal-title":"Arch Ophthalmol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2023.1116391","article-title":"Advances in application of swept-source optical coherence tomography angiography in diagnosis and treatment of diabetic retinopathy","volume":"3","author":"Zhang J","year":"2023","unstructured":"Zhang J, Huo Q, Xia D, Wang M, Li X. Advances in application of swept-source optical coherence tomography angiography in diagnosis and treatment of diabetic retinopathy. Front Ophthalmol (Lausanne). 2023, 3:1116391. 10.3389\/fopht.2023.1116391","journal-title":"Front Ophthalmol (Lausanne)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000003542","article-title":"Is meibomian gland dysfunction one disease? Heterogeneity among phenotypes","volume":"43","author":"Kim CK","year":"2024","unstructured":"Kim CK, Locatelli EV, Prislovsky A, Cabrera K, Gary AA, Mandal N, Galor A. Is meibomian gland dysfunction one disease? Heterogeneity among phenotypes. Cornea. 2024, 43:1410-7. 10.1097\/ICO.0000000000003542","journal-title":"Cornea"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.973962","article-title":"Response of tear cytokines following intense pulsed light combined with meibomian gland expression for treating meibomian gland dysfunction-related dry eye","volume":"13","author":"Yu H","year":"2022","unstructured":"Yu H, Zeng W, Zhao G, Hong J, Feng Y. Response of tear cytokines following intense pulsed light combined with meibomian gland expression for treating meibomian gland dysfunction-related dry eye. Front Endocrinol (Lausanne). 2022, 13:973962. 10.3389\/fendo.2022.973962","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.05.039","article-title":"TFOS DEWS III: management and therapy","volume":"279","author":"Jones L","year":"2025","unstructured":"Jones L, Craig JP, Markoulli M, et al.. TFOS DEWS III: management and therapy. Am J Ophthalmol. 2025, 279:289-386. 10.1016\/j.ajo.2025.05.039","journal-title":"Am J Ophthalmol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.05.033","article-title":"TFOS DEWS III: diagnostic methodology","volume":"279","author":"Wolffsohn JS","year":"2025","unstructured":"Wolffsohn JS, Ben\u00edtez-Del-Castillo JM, Loya-Garcia D, et al.. TFOS DEWS III: diagnostic methodology. Am J Ophthalmol. 2025, 279:387-450. 10.1016\/j.ajo.2025.05.033","journal-title":"Am J Ophthalmol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron AJ","year":"2017","unstructured":"Bron AJ, de Paiva CS, Chauhan SK, et al.. TFOS DEWS II pathophysiology report. Ocul Surf. 2017, 15:438-510. 10.1016\/j.jtos.2017.05.011","journal-title":"Ocul Surf"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000351","article-title":"Meibomian gland dysfunction and contact lens discomfort","volume":"43","author":"Arita R","year":"2017","unstructured":"Arita R, Fukuoka S, Morishige N. Meibomian gland dysfunction and contact lens discomfort. Eye Contact Lens. 2017, 43:17-22. 10.1097\/ICL.0000000000000351","journal-title":"Eye Contact Lens"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.004","article-title":"TFOS DEWS II iatrogenic report","volume":"15","author":"Gomes JA","year":"2017","unstructured":"Gomes JA, Azar DT, Baudouin C, et al.. TFOS DEWS II iatrogenic report. Ocul Surf. 2017, 15:511-38. 10.1016\/j.jtos.2017.05.004","journal-title":"Ocul Surf"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2020.0014","article-title":"Loteprednol etabonate for the treatment of dry eye disease","volume":"36","author":"Beckman K","year":"2020","unstructured":"Beckman K, Katz J, Majmudar P, Rostov A. Loteprednol etabonate for the treatment of dry eye disease. J Ocul Pharmacol Ther. 2020, 36:497-511. 10.1089\/jop.2020.0014","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2019.08.007","article-title":"Management of meibomian gland dysfunction: a review","volume":"65","author":"Sabeti S","year":"2020","unstructured":"Sabeti S, Kheirkhah A, Yin J, Dana R. Management of meibomian gland dysfunction: a review. Surv Ophthalmol. 2020, 65:205-17. 10.1016\/j.survophthal.2019.08.007","journal-title":"Surv Ophthalmol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s10103-024-04154-4","article-title":"Effects of combined intense pulsed light and cyclosporine 0.05% eyedrops in ocular surface matrix metalloproteinase-9 levels in patients with moderate-to-severe MGD","volume":"39","author":"Jeon YY","year":"2024","unstructured":"Jeon YY, Bae S, Chung HS, Kim JY, Lee H. Effects of combined intense pulsed light and cyclosporine 0.05% eyedrops in ocular surface matrix metalloproteinase-9 levels in patients with moderate-to-severe MGD. Lasers Med Sci. 2024, 39:203. 10.1007\/s10103-024-04154-4","journal-title":"Lasers Med Sci"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1177\/11206721221128995","article-title":"Evaluation of warm compresses and topical cyclosporine treatment in meibomian gland dysfunction by confocal scanning laser microscopy","volume":"33","author":"Iaccheri B","year":"2022","unstructured":"Iaccheri B, Torroni G, Cerquaglia A, et al.. Evaluation of warm compresses and topical cyclosporine treatment in meibomian gland dysfunction by confocal scanning laser microscopy. Eur J Ophthalmol. 2022, 33:881-9. 10.1177\/11206721221128995","journal-title":"Eur J Ophthalmol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1177\/11206721221141481","article-title":"Management of inflammation in dry eye disease: recommendations from a European panel of experts","volume":"33","author":"Messmer EM","year":"2023","unstructured":"Messmer EM, Ahmad S, Benitez Del Castillo JM, Mrukwa-Kominek E, Rolando M, Vitovska O, Baudouin C. Management of inflammation in dry eye disease: recommendations from a European panel of experts. Eur J Ophthalmol. 2023, 33:1294-307. 10.1177\/11206721221141481","journal-title":"Eur J Ophthalmol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.882803","article-title":"Comparison of seven cyclosporine A formulations for dry eye disease: a systematic review and network meta-analysis","volume":"13","author":"Gao D","year":"2022","unstructured":"Gao D, Da Z, Yang K, Shi Y. Comparison of seven cyclosporine A formulations for dry eye disease: a systematic review and network meta-analysis. Front Pharmacol. 2022, 13:882803. 10.3389\/fphar.2022.882803","journal-title":"Front Pharmacol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-022-00906-3","article-title":"Efficacy of a 0.05% cyclosporine a topical nanoemulsion in dry eyes with obstructive meibomian gland dysfunction","volume":"66","author":"Rhim JW","year":"2022","unstructured":"Rhim JW, Eom Y, Yoon EG, Park SY, Choi Y, Song JS, Kim HM. Efficacy of a 0.05% cyclosporine a topical nanoemulsion in dry eyes with obstructive meibomian gland dysfunction. Jpn J Ophthalmol. 2022, 66:254-63. 10.1007\/s10384-022-00906-3","journal-title":"Jpn J Ophthalmol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41038","article-title":"Topical spironolactone in the treatment of evaporative dry eye disease","volume":"15","author":"Wong CW","year":"2023","unstructured":"Wong CW, Wong BS, Ali W, De Jesus ML, Melber TA, Yee RW. Topical spironolactone in the treatment of evaporative dry eye disease. Cureus. 2023, 15:e41038. 10.7759\/cureus.41038","journal-title":"Cureus"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.895418","article-title":"Bevacizumab eye drops vs. intra-meibomian gland injection of bevacizumab for meibomian gland dysfunction-associated posterior blepharitis","volume":"9","author":"Tantipat C","year":"2022","unstructured":"Tantipat C, Kasetsuwan N, Chotikkakamthorn P, Pongpirul K. Bevacizumab eye drops vs. intra-meibomian gland injection of bevacizumab for meibomian gland dysfunction-associated posterior blepharitis. Front Med (Lausanne). 2022, 9:895418. 10.3389\/fmed.2022.895418","journal-title":"Front Med (Lausanne)"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1177\/1120672118817687","article-title":"Intense regulated pulse light for the meibomian gland dysfunction","volume":"30","author":"Karaca EE","year":"2020","unstructured":"Karaca EE, Evren Kemer \u00d6, \u00d6zek D. Intense regulated pulse light for the meibomian gland dysfunction. Eur J Ophthalmol. 2020, 30:289-92. 10.1177\/1120672118817687","journal-title":"Eur J Ophthalmol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000001055","article-title":"Intense pulsed light treatment for the management of meibomian gland dysfunction","volume":"35","author":"Gupta AS","year":"2024","unstructured":"Gupta AS, Massaro M, Bunya VY. Intense pulsed light treatment for the management of meibomian gland dysfunction. Curr Opin Ophthalmol. 2024, 35:322-8. 10.1097\/ICU.0000000000001055","journal-title":"Curr Opin Ophthalmol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17986-3","article-title":"Efficacy and safety of intense pulsed light direct eyelid application","volume":"12","author":"Mart\u00ednez-Hergueta MC","year":"2022","unstructured":"Mart\u00ednez-Hergueta MC, Ali\u00f3 Del Barrio JL, Canto-Cerdan M, Amesty MA. Efficacy and safety of intense pulsed light direct eyelid application. Sci Rep. 2022, 12:15592. 10.1038\/s41598-022-17986-3","journal-title":"Sci Rep"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-33526-z","article-title":"Comparison of clinical outcomes between intense pulsed light therapy using two different filters in meibomian gland dysfunction: prospective randomized study","volume":"13","author":"Jang JH","year":"2023","unstructured":"Jang JH, Lee K, Nam SH, Kim J, Kim JY, Tchah H, Lee H. Comparison of clinical outcomes between intense pulsed light therapy using two different filters in meibomian gland dysfunction: prospective randomized study. Sci Rep. 2023, 13:6700. 10.1038\/s41598-023-33526-z","journal-title":"Sci Rep"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-020-04834-1","article-title":"Intense pulsed light for meibomian gland dysfunction: a systematic review and meta-analysis","volume":"259","author":"Leng X","year":"2021","unstructured":"Leng X, Shi M, Liu X, Cui J, Sun H, Lu X. Intense pulsed light for meibomian gland dysfunction: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2021, 259:1-10. 10.1007\/s00417-020-04834-1","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1111\/aos.16802","article-title":"Effectiveness and safety of intense pulsed light therapy for dry eye symptoms due to meibomian gland dysfunction: a systematic review and meta\u2010analysis","volume":"103","author":"Peira N","year":"2025","unstructured":"Peira N, Ali EM, Mod\u00e9n NK, Fjellgren E, Lennmarken C, Hultcrantz M. Effectiveness and safety of intense pulsed light therapy for dry eye symptoms due to meibomian gland dysfunction: a systematic review and meta\u2010analysis. Acta Ophthalmol. 2025, 103:371-9. 10.1111\/aos.16802","journal-title":"Acta Ophthalmol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000947","article-title":"Macular hole formation associated with intense pulsed light therapy","volume":"16","author":"Maganti N","year":"2022","unstructured":"Maganti N, Kalbag NS, Gill MK. Macular hole formation associated with intense pulsed light therapy. Retin Cases Brief Rep. 2022, 16:161-4. 10.1097\/ICB.0000000000000947","journal-title":"Retin Cases Brief Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/414204-the-role-of-eyelid-margin-vascularity-in-meibomian-gland-dysfunction-diagnosis-and-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T18:17:08Z","timestamp":1759256228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/414204-the-role-of-eyelid-margin-vascularity-in-meibomian-gland-dysfunction-diagnosis-and-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":57,"URL":"https:\/\/doi.org\/10.7759\/cureus.93587","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}